Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours
Status:
Unknown status
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
To assess the activity of the FGFR inhibitor AZD4547 in patients with FGFR1 or FGFR2
amplified breast, squamous lung and stomach cancer whose cancers have progressed following
previous chemotherapy